| Polatuzumab Vedotin studied in …STUDIED_INderived70 of 70show fewer |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | Aggressive Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04679012Phase 2 · active not recruiting Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation · 70 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890884Phase 2 · recruiting A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) · 70 trials list this drug (46 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · 70 trials list this drug (46 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594798Phase 2 · active not recruiting A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05615636Phase 2 · recruiting A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma,Diffuse Large B-Cell Lymphoma,Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06047080Phase 3 · active not recruiting An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07308132Phase 1 · recruiting A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06594939Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171647Phase 3 · active not recruiting A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07397832Phase 2 · recruiting CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07654426Phase 2 · recruiting The CARDIOPROTECT Trial · 70 trials list this drug (46 active) | — | — | Lymphoma,Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07717177Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04884035Phase 1 · active not recruiting Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04970901Phase 1 · active not recruiting A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) · 70 trials list this drug (46 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638722Phase 2 · not yet recruiting Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment · 70 trials list this drug (46 active) | — | — | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Splenic Marginal Zone Lymphoma,Nodal Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015880Phase 1 · recruiting Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05283720Phase 2 · active not recruiting A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03533283Phase 1/Phase 2 · active not recruiting An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954910recruiting A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06040320Phase 1/Phase 2 · active not recruiting Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD) · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638787Phase 1/Phase 2 · not yet recruiting Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04833114Phase 3 · completed Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07594899Phase 2 · not yet recruiting AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06730542Phase 1 · recruiting Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma · 70 trials list this drug (46 active) | — | — | Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma,Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Indolent B-Cell Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03274492Phase 3 · completed A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498220Phase 2 · terminated Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491370Phase 1/Phase 2 · recruiting Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Hodgkin Lymphoma,Transformed Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05798156Phase 2 · active not recruiting Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP · 70 trials list this drug (46 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07415980Phase 1/Phase 2 · not yet recruiting Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04323956Phase 1 · active not recruiting Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Indolent Non-Hodgkin Lymphoma,High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Primary Mediastinal Large B-Cell Lymphoma,Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043674Phase 2 · recruiting Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation · 70 trials list this drug (46 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04182204Phase 3 · completed A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05410418Phase 2 · active not recruiting Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma · 70 trials list this drug (46 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06803693Phase 2 · recruiting Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04607772Phase 1/Phase 2 · withdrawn Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479267Phase 2 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Double-Expressor Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03677154Phase 1/Phase 2 · completed Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07122609Phase 2 · not yet recruiting Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07034508Phase 2 · not yet recruiting A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1 · 70 trials list this drug (46 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07012980Phase 2 · not yet recruiting Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06530511Phase 2 · unknown Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03467373Phase 1 · completed A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06071871Phase 2 · recruiting A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03677141Phase 1/Phase 2 · completed A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03671018Phase 1/Phase 2 · active not recruiting A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04659044Phase 2 · terminated Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Small Lymphocytic Lymphoma,Mantle Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06554600Phase 2 · recruiting A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04914741Phase 1/Phase 2 · unknown A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06516978Phase 2 · not yet recruiting A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04790903Phase 1 · terminated A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441097Phase 2 · not yet recruiting Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02600897Phase 1/Phase 2 · completed A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02611323Phase 1/Phase 2 · completed A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01992653Phase 1/Phase 2 · completed A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04236141Phase 3 · terminated A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257567Phase 1/Phase 2 · completed A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma · 70 trials list this drug (46 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04535102Phase 2 · withdrawn POLA+BR for Relapsed or Refractory DLBCL · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04882163Phase 1/Phase 2 · withdrawn Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma · 70 trials list this drug (46 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04913103Phase 2 · not yet recruiting Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL · 70 trials list this drug (46 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02729896Phase 1/Phase 2 · completed A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · 70 trials list this drug (46 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04624893unknown A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01691898Phase 1/Phase 2 · completed A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · 70 trials list this drug (46 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01290549Phase 1 · completed A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma · 70 trials list this drug (46 active) | — | — | Non-Hodgkin Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |